Abemaciclib

BreastfeedingPediatric
  • TRADE NAME: Verzenio (Lilly)
  • INDICATIONS: Hormone receptor-positive, human epidermal growth factor 2-negative advanced or metastatic breast cancer, either as monotherapy or in combination with fulvestrant; or as inital endocrine-based therapy with an aromatase inhibitor
  • CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
  • HALF-LIFE: 18 hours

FDA APPROVAL DATE: 09/28/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Grapefruit Juice, Ketoconazole, Strong CYP3A4 inducers or inhibitors

PREGNANCY CATEGORY: N/A
Can cause fetal harm

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top